H. Lundbeck A/s

This study tests a new medicine called Lu AG13909 in 18 adults with Cushing's disease, a rare condition where the body makes too much cortisol. The goal is to see if the drug can safely lower cortisol levels to normal. Researchers will also measure how the drug moves through the …

This study tests whether eptinezumab, given as an IV infusion, can prevent migraines in children aged 6 to 17 with episodic migraine. About 315 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the number of migraine days per mont…

This study tests a new medicine called Lu AG13909 in adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The main goals are to see if the drug is safe, how it moves through the body, and how it affects hormone levels. About…

This study looks at the long-term safety of eptinezumab in 600 children and teens aged 6 to 17 who have chronic or episodic migraine. Participants must have completed a previous study of the same drug. The main goal is to track side effects over time, with additional measures of …

This study tests whether eptinezumab, given as an IV infusion, can reduce the number of migraine days in teenagers aged 12 to 17 who have chronic migraines (15 or more headache days per month). Participants will receive either the drug or a placebo (salt water) and will be follow…